Jo Cox

Jo is an Executive Medical Director at tranScrip, bringing over 20 years of experience as a pharmaceutical physician. She has held cross-functional leadership roles in clinical development, medical affairs, and pharmacovigilance across a range of therapeutic areas, with a particular focus on Women’s Health. Her expertise includes providing medical input into regulatory submissions in the US, Europe, and Japan. 

Previously, Jo served as a Medical Fellow at Eli Lilly and Company in Global Oncology Clinical Development, where she was the Medical Lead for a global Phase 3 study in early breast cancer. Before that, she worked as a Global Oncology Patient Safety Physician, responsible for the ongoing pharmacovigilance of oncology compounds across all phases of development, including submission-related activities. 

Jo has strong expertise in the analysis and interpretation of safety data from Phase 2 and 3 trials. She has co-authored key components of clinical submission dossiers, including the Summary of Clinical Safety, Clinical Overview, Risk Management Plans, and the Core Data Sheet. She is experienced in regulatory interactions, including presenting safety data to the FDA, EU Rapporteur and Co-Rapporteur, responding to regulatory queries, and labelling negotiations. 

Her clinical background is in Obstetrics and Gynaecology, primarily within the UK NHS, as well as two years of practice in Australia. Upon joining Lilly UK, Jo worked in medical affairs across the Women’s Health portfolio, as well as in diabetes, urology, and cardiovascular therapy areas. Her responsibilities included supporting product launches, leading Advisory Boards, developing publication strategies, and providing medical input into the development and approval of promotional materials. 

Jo has also recruited and managed medical teams, including physicians, clinical research scientists, and medical science liaisons. 

Jo is a member of the Royal College of Obstetricians and Gynaecologists and the Faculty of Pharmaceutical Medicine. She has previously served on the FPM Women and Children’s Health Expert Panel and the NICE Guideline Review Panel for Women and Children’s Health.